Monoclonal gammopathies of undetermined significance

Robert A. Kyle, S Vincent Rajkumar

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenström's macroglobulinemia (WM). At Mayo Clinic, almost 60% of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10% plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year.

Original languageEnglish (US)
Pages (from-to)689-707
Number of pages19
JournalBest Practice and Research: Clinical Haematology
Volume18
Issue number4 SPEC. ISS.
DOIs
StatePublished - Dec 2005

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Plasmas
Plasma Cells
Bone
Waldenstrom Macroglobulinemia
Paraproteinemias
Multiple Myeloma
Proteins
Hypercalcemia
Amyloidosis
Renal Insufficiency
Anemia
Blood Proteins
Bone Marrow
Urine
Bone and Bones
Population

Keywords

  • Monoclonal gammopathy
  • Monoclonal gammopathy of undetermined significance (MGUS)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Monoclonal gammopathies of undetermined significance. / Kyle, Robert A.; Rajkumar, S Vincent.

In: Best Practice and Research: Clinical Haematology, Vol. 18, No. 4 SPEC. ISS., 12.2005, p. 689-707.

Research output: Contribution to journalArticle

@article{c89fd1ae48494a2aaf62b9c516431109,
title = "Monoclonal gammopathies of undetermined significance",
abstract = "The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenstr{\"o}m's macroglobulinemia (WM). At Mayo Clinic, almost 60{\%} of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10{\%} plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1{\%} per year.",
keywords = "Monoclonal gammopathy, Monoclonal gammopathy of undetermined significance (MGUS)",
author = "Kyle, {Robert A.} and Rajkumar, {S Vincent}",
year = "2005",
month = "12",
doi = "10.1016/j.beha.2005.01.025",
language = "English (US)",
volume = "18",
pages = "689--707",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4 SPEC. ISS.",

}

TY - JOUR

T1 - Monoclonal gammopathies of undetermined significance

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

PY - 2005/12

Y1 - 2005/12

N2 - The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenström's macroglobulinemia (WM). At Mayo Clinic, almost 60% of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10% plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year.

AB - The monoclonal gammopathies include multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), primary systemic amyloidosis (AL), and Waldenström's macroglobulinemia (WM). At Mayo Clinic, almost 60% of patients with a monoclonal gammopathy have MGUS. MGUS is characterized by the presence of a serum monoclonal protein value <3 g/dL, fewer than 10% plasma cells in the bone marrow, no or a small amount of monoclonal protein in the urine, and absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the plasma-cell proliferative process. During long-term follow-up of 241 patients with MGUS seen at Mayo Clinic from 1956 to 1970, MM, WM, AL, or a related disorder developed in 64. To confirm the findings, we conducted a population-based study on MGUS in the 11 counties of southeastern Minnesota from 1960 to 1994. The risk of progression to a malignant plasma-cell disorder was 1% per year.

KW - Monoclonal gammopathy

KW - Monoclonal gammopathy of undetermined significance (MGUS)

UR - http://www.scopus.com/inward/record.url?scp=22144434741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144434741&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2005.01.025

DO - 10.1016/j.beha.2005.01.025

M3 - Article

C2 - 16026745

AN - SCOPUS:22144434741

VL - 18

SP - 689

EP - 707

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4 SPEC. ISS.

ER -